Systemic sclerosis & Raynaud's
Gut microbiota in very early systemic sclerosis: the first case-control taxonomic and functional characterisation highlighting an altered butyric acid profile
Authors' conclusion
A GM dysbiosis with depletion of beneficial anti-inflammatory bacteria (especially butyrate-producing) and a significant decrease in faecal butyrate was identified in patients with VEDOSS.
Study context
- Population
- Patients with very early diagnosis of SSc (VEDOSS) and definite systemic sclerosis (SSc), and healthy controlsstool samples
- Participants
- 18 / 26 / 20
- Comparison
- VEDOSS and definite SSc vs healthy controls
- VEDOSSn = 18
- SScn = 26
- Healthy controls (HC)n = 20reference
- Outcome
- Gut microbiota composition, faecal short-chain fatty acids and host-derived free fatty acids
Methodological details16S rRNA sequencing, gas chromatography-mass spectrometry
- 16S rRNA sequencing
- Gas chromatography-mass spectrometry
Main finding
As reported in the abstract
Gut microbiota and faecal fatty acids
- VEDOSS vs HC: increased Bacteroidales and Oscillospirales; decreased Bacilli, Blautia, Romboutsia, Streptococcus and Turicibacter
- SSc vs HC: increased Acidaminococcaceae and Sutterellaceae; decreased Peptostreptococcaceae, Anaerostipes, Blautia, Romboutsia and Turicibacter
- SSc and VEDOSS vs HC: significantly lower butyrate and higher acetate
- VEDOSS vs SSc: increased Oscillospiraceae and Anaerostipes; decreased Alphaproteobacteria and Lactobacillales
- VEDOSS vs SSc: higher acetate and lower valerate
Observational data: associations, not effects.
Original publication
Gut microbiota in very early systemic sclerosis: the first case-control taxonomic and functional characterisation highlighting an altered butyric acid profile. RMD Open. Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →